MarketsNath Bio-Genes (India) Limited NATHBIOGEN
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Daily technical summary
Calculated in the browser from validated historical candles. This is descriptive research, not a buy or sell recommendation.
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,097.42 | 1,026.21 | 880.23 |
| Cash Equivalents | 76 | 87.05 | 74.01 |
| Other Liabilities Total | 4.95 | 3.54 | 3 |
| Long Term Debt | 17.32 | 11.37 | 2.04 |
| Common Stock Total | 19 | 19 | 19 |
| Other Current Assets Total | 2.5 | 0.37 | Not available |
| Total Assets | 1,097.42 | 1,026.21 | 880.23 |
| Current Portof LT Debt/Capital Leases | 121.18 | 1.38 | 1.35 |
| Total Equity | 680.46 | 644.39 | 609.92 |
| Long Term Investments | 26.51 | 5.78 | 6.05 |
| Retained Earnings(Accumulated Deficit) | 661.45 | 491.88 | 457.08 |
| Total Common Shares Outstanding | 1.9 | 1.9 | 1.9 |
| Tangible Book Valueper Share Common Eq | 355.12 | 335.3 | 316.31 |
| Total Liabilities | 416.96 | 381.82 | 270.31 |
| Total Debt | 138.5 | 122.5 | 110.35 |
| Short Term Investments | 163.42 | 0.01 | 0.01 |
| Cashand Short Term Investments | 239.42 | 88.53 | 77.41 |
| Total Receivables Net | 86.39 | 98.69 | 102.11 |
| Accounts Receivable-Trade Net | 85.41 | 90.41 | 94.31 |
| Property/Plant/Equipment Total-Net | 243.82 | 243.19 | 240.65 |
| Total Current Liabilities | 394.7 | 365.3 | 262.45 |
| Total Inventory | 450.55 | 501.99 | 391.86 |
| Accounts Payable | 131.12 | 79.48 | 43.3 |
| Other Currentliabilities Total | 142.4 | 164.47 | 113.67 |
| Total Long Term Debt | 17.32 | 12.98 | 4.87 |
| Intangibles Net | 5.59 | 7.18 | 8.81 |
| Other Long Term Assets Total | 42.64 | 1.29 | 1.28 |
| Total Current Assets | 778.86 | 690.01 | 571.66 |
| Accumulated Depreciation Total | Not available | -19.71 | -17.53 |
| Accrued Expenses | Not available | 11.83 | Not available |
| Other Equity Total | Not available | 0 | 0.33 |
| Prepaid Expenses | Not available | 0.43 | 0.29 |
| Additional Paid-In Capital | Not available | 133.5 | 133.5 |
| Cash | Not available | 1.48 | 3.39 |
| Property/Plant/Equipment Total-Gross | Not available | 262.91 | 258.18 |
| Notes Payable/Short Term Debt | Not available | 108.14 | 104.13 |
| Note Receivable-Long Term | Not available | 78.76 | 51.78 |
| Capital Lease Obligations | Not available | 1.61 | 2.83 |
Valuation and ratios
Valuation
Price to Sale Ratio0.70
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk43.19
Recommendations
Target High207
Target Low126.75
Target Mean0
Target Median0
Analyst count, source and as-of date are not provided; target values should be treated as unverified.Peer comparison
Only peers present in the company profile payload are displayed.
Ownership
- Promoter
- 45.60%
- FII
- 0.26%
- MF
- 0.01%
- Other
- 54.13%
Events
- board MeetingsQuarterly Results
- dividendRs.2.0000 per share(20%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.2.0000 per share(20%)Final Dividend
- board MeetingsQuarterly Results
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.2.0000 per share(20%)Final Dividend
- board MeetingsQuarterly Results
- board MeetingsAudited Results & Final Dividend
- annual General MeetingEGM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingRs.2.0000 per share(20%)Final Dividend & A.G.M. (Revised)
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Nath Bio-Genes (India) Ltd is Rated Sell Markets Mojo
Nath Bio-Genes (India) Ltd Upgraded to Hold on Technical and Valuation Improvements Markets Mojo
Golden Cross Confirmed: Do Nath Bio-Genes' Other Technical Indicators Agree? Markets Mojo
Nath Bio-Genes (India) Ltd Upgraded to Sell on Technical Improvement Despite Weak Fundamentals Markets Mojo
Nath Bio-Genes (India) Ltd is Rated Strong Sell Markets Mojo
Nath Bio-Genes Q4 FY26 Earnings Call: Revenue Up 19%, Audio Recording Submitted scanx.trade
Nath Bio-Genes Reports Flat Quarterly Performance Amid Mixed Financial Trends Markets Mojo
Nath Bio-Genes Consolidated March 2026 Net Sales at Rs 51.59 crore, down 0.72% Y-o-Y Moneycontrol.com
Business information
Nath Bio-Genes (India) Limited market prices and historical candles are loaded from the ShareKeyX Supabase market database.
- Industry
- Crops
- Sector
- Crops
- Website
- Not available
- Address
- Not available
- NSE Code
- NATHBIOGEN
- BSE Code
- 537291
AI analysis
This repository contains no authenticated model-inference API, model version, confidence distribution or forecast timestamp. The Android listing is available; verify report availability, entitlement and pricing inside the app.
Open Google PlayStock FAQ
What is the symbol and ISIN of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd has the symbol NATHBIOGEN and ISIN - INE448G01010.
What is the current price of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd is currently trading at INR 162.00.
What are the year high and year low of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd has a year high of INR 207.00 and a year low of INR 126.75.
What is the market capitalization of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd has a market capitalization of INR 311.58 crore.
What is the P/E ratio of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd has a P/E ratio of NA.
What is the dividend yield of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd has a dividend yield of NA.
How is the financial performance of Nath Bio-Genes (India) Ltd based on revenue, net income, and EPS?
Nath Bio-Genes (India) Ltd has revenue of INR 445.10 crore, net income of INR 41.63 crore, and EPS of NA.
What is the book value of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd has a book value of NA.
What is the debt-to-equity ratio of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd has a price-to-book ratio of NA and a price-to-sales ratio of 0.70.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.
